Clinical Trials Logo

Essential Hypertension clinical trials

View clinical trials related to Essential Hypertension.

Filter by:

NCT ID: NCT03514641 Active, not recruiting - Clinical trials for Essential Hypertension

An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension

Start date: October 18, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This integrated assessment consists of two studies, 603A and 603B, to be carried out sequentially in a common study population. Participating subjects will be informed of the trial design and their consent to participate in both studies will be obtained in a single consent form. Approximately 680 male or female adult subjects will be enrolled.

NCT ID: NCT03371797 Recruiting - Clinical trials for Essential Hypertension

Amlodipine VaLsartan Efficacy in Hypertensive Patients.A Real World Trial

ALERT
Start date: February 20, 2018
Phase:
Study type: Observational

To determine the efficacy of valsartan/amlodipine 80/5 mg once daily dose is reducing mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) after 8 weeks of therapy.

NCT ID: NCT03226340 Recruiting - Clinical trials for Essential Hypertension

S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension

Start date: December 2, 2015
Phase: Phase 4
Study type: Interventional

Evaluation of the Efficacy and Safety of S-amlodipine+Chlorthalidone Combination Therapy and S-amlodipine+Telmisartan Combination Therapy in Hypertensive Patients Inadequately Controlled With CCB(Calcium Channel Blocker) Monotherapy

NCT ID: NCT03156842 Recruiting - Dyslipidemia Clinical Trials

Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia

FIRST
Start date: May 29, 2017
Phase: Phase 3
Study type: Interventional

The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/amlodipine/rosuvastatin treatment group to the fimasartan/amlodipine treatment group and the fimasartan/rosuvastatin treatment group respectively at Week 8 in patients with essential hypertension and dyslipidemia who fail to respond to the fimasartan monotherapy.

NCT ID: NCT03063697 Enrolling by invitation - Clinical trials for Congestive Heart Failure

Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure

DELIGHT
Start date: November 2015
Phase: N/A
Study type: Observational

The purpose of this study is to Evaluate the Safety of DILATREND SR Cap. in Korean Patients with Essential hypertension, Chronic stable angina and Congestive heart failure for 52 weeks.

NCT ID: NCT02944734 Completed - Clinical trials for Essential Hypertension

Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension

Start date: September 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the optimal dose of fixed-dose combination of candesartan cilexetil and amlodipine besylate by examining the safety and efficacy of the combination therapy compared to each of the monotherapy in patients with essential hypertension.

NCT ID: NCT02938910 Completed - Healthy Clinical Trials

Study of Myocardial Interstitial Fibrosis in Hyperaldosteronism

COEURALDO
Start date: November 2012
Phase: N/A
Study type: Observational

Animal models have demonstrated the role of aldosterone in left ventricular remodeling involving fibrosis, apoptosis and hypertrophy. Myocardial fibrosis is a risk factor for serious arrhythmia and sudden death in ischemic and idiopathic hypertrophic heart disease. It is accepted that patients with primary aldosteronism have a higher prevalence of LV hypertrophy , arterial involvement and increased cardiovascular risk. In humans, a link has been demonstrated between aldosterone and heart failure as well as the benefit of the administration of an anti -aldosterone drug to lower mortality in this population , regardless of blood pressure level . The administration of spironolactone ( aldosterone ) in hypertensive rats has prevented the occurrence of aortic fibrosis . Plasma aldosteronism in humans has been associated with inflammation, fibrosis and aortic stiffness . However, primary aldosteronism is generally associated with so-called secondary hypertension . Chronic hypertension alone is a recognized etiological factor of myocardial hypertrophy ( myocardial fibrosis very advanced ) . The purpose of this study is to investigate the effects of MRI hyperaldosteronism on the heart.

NCT ID: NCT02890173 Completed - Clinical trials for Essential Hypertension

Study of CS-3150 in Patients With Essential Hypertension

ESAX-HTN
Start date: September 2016
Phase: Phase 3
Study type: Interventional

To evaluate antihypertensive effect and safety of CS-3150 compared to Eplerenone in patients with essential hypertension.

NCT ID: NCT02848170 Completed - Clinical trials for Essential Hypertension

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

Start date: August 2016
Phase: N/A
Study type: Interventional

Phase 3 study to examine the relation between antihypertensive effect and baseline factors exploratively, compared to olmesartan medoxomil in patients with essential hypertension.

NCT ID: NCT02839382 Active, not recruiting - Clinical trials for Cardiovascular Disease

The Northwest Coalition for Primary Care Practice Support

H2N
Start date: May 2015
Phase: N/A
Study type: Interventional

The purpose of this project is to build capacity for quality improvement (QI) in small primary care practices across Washington, Oregon and Idaho by improving risk factors for heart attacks such as blood pressure, cholesterol and smoking. The Northwest Coalition for Primary Care Practice Support will assist practices by providing them with a QI coach, creating group learning opportunities, and conducting educational outreach activities. An innovative study design will be used to determine what levels and types of support are most helpful and effective.